Case Report: The JAK-Inhibitor Ruxolitinib Use in Aicardi-Goutieres Syndrome Due to ADAR1 Mutation

MLA

Marco Cattalini, et al. “Case Report: The JAK-Inhibitor Ruxolitinib Use in Aicardi-Goutieres Syndrome Due to ADAR1 Mutation.” Frontiers in Pediatrics, vol. 9, Oct. 2021. EBSCOhost, https://doi.org/10.3389/fped.2021.725868.

APA

Marco Cattalini, Jessica Galli, Fiammetta Zunica, Rosalba Monica Ferraro, Marialuisa Carpanelli, Simona Orcesi, Giovanni Palumbo, Lorenzo Pinelli, Silvia Giliani, Elisa Fazzi, & Raffaele Badolato. (2021). Case Report: The JAK-Inhibitor Ruxolitinib Use in Aicardi-Goutieres Syndrome Due to ADAR1 Mutation. Frontiers in Pediatrics, 9. https://doi.org/10.3389/fped.2021.725868

Chicago

Marco Cattalini, Jessica Galli, Fiammetta Zunica, Rosalba Monica Ferraro, Marialuisa Carpanelli, Simona Orcesi, Giovanni Palumbo, et al. 2021. “Case Report: The JAK-Inhibitor Ruxolitinib Use in Aicardi-Goutieres Syndrome Due to ADAR1 Mutation.” Frontiers in Pediatrics 9 (October). doi:10.3389/fped.2021.725868.